Beckley Psytech has released initial positive findings from its Phase IIa clinical study of BPL-003 for treating treatment-resistant depression (TRD).
The open-label trial assessed the safety, efficacy, and pharmacokinetics of a single 10mg intranasal dose of BPL-003, a synthetic benzoate salt formulation of 5-MeO-DMT, alongside psychological support.
Go deeper with GlobalData
It enrolled 12 subjects with moderate-to-severe TRD, not receiving other antidepressants.
Following the dosing, patients were monitored for 12 weeks with regular assessments.
Early analysis revealed a rapid antidepressant response in 55% of patients by the second day.
The findings highlight BPL-003’s potential, with a significant number of patients showing remission from depression nearly a month after treatment.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe treatment was also found to be well-tolerated, with the majority of side effects being mild or moderate and no serious adverse events reported.
Beckley Psytech is optimistic about these results, which could pave the way for a scalable single-dose treatment model.
Based on these data, the company will extend the Phase IIa study to include patients on stable oral antidepressants, aiming to evaluate BPL-003 as an adjunctive therapy.
The upcoming multi-centre Phase IIb trial will validate the safety and efficacy of medium or high doses of BPL-003 versus a sub-perceptual dose in 225 TRD patients.
Results from this trial are anticipated in the second half of this year.
Beckley Psytech CEO Cosmo Feilding Mellen said: “We are delighted to see that a single dose of BPL-003 delivered a rapid and durable antidepressant response in patients with treatment-resistant depression.
“Our single-dose treatment model enables a short treatment duration, which positions BPL-003 as a potentially exciting and scalable treatment opportunity.
“Less than 15% of patients with treatment-resistant depression achieve long-term remission with the current standard of care, and we look forward to further validating the potential of BPL-003 as a treatment option with our ongoing Phase IIb study and subsequent clinical development programme.”
In April 2023, the company commenced a Phase IIa trial of its fast-acting psychedelic compound for treating alcohol use disorder.
